Clear Creek Financial Management LLC Has $527,000 Holdings in Pfizer Inc. (NYSE:PFE)

Clear Creek Financial Management LLC decreased its position in Pfizer Inc. (NYSE:PFE) by 52.9% during the 4th quarter, Holdings Channel.com reports. The firm owned 19,869 shares of the biopharmaceutical company’s stock after selling 22,336 shares during the period. Clear Creek Financial Management LLC’s holdings in Pfizer were worth $527,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently made changes to their positions in PFE. Retirement Wealth Solutions LLC bought a new position in Pfizer during the 4th quarter worth $26,000. Gladius Capital Management LP grew its stake in shares of Pfizer by 102.8% in the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 38,015 shares in the last quarter. Quarry LP bought a new position in Pfizer during the second quarter worth about $31,000. Teachers Insurance & Annuity Association of America acquired a new stake in Pfizer in the 3rd quarter worth about $35,000. Finally, Joseph Group Capital Management boosted its holdings in Pfizer by 168.3% in the 3rd quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 771 shares during the period. Institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

PFE stock opened at $26.51 on Monday. The stock has a market cap of $150.20 billion, a price-to-earnings ratio of 35.82, a P/E/G ratio of 0.64 and a beta of 0.64. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The company has a 50 day simple moving average of $26.27 and a 200 day simple moving average of $27.86. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54.

Pfizer Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be issued a dividend of $0.43 per share. This is an increase from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.49%. Pfizer’s dividend payout ratio (DPR) is 232.44%.

Analysts Set New Price Targets

PFE has been the subject of a number of analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research report on Wednesday, October 23rd. Citigroup dropped their price objective on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a report on Tuesday, January 28th. Bank of America reissued a “neutral” rating and set a $29.00 target price on shares of Pfizer in a report on Tuesday, December 10th. Guggenheim cut their price objective on shares of Pfizer from $35.00 to $33.00 and set a “buy” rating for the company in a research report on Wednesday, December 11th. Finally, UBS Group decreased their target price on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a report on Wednesday, January 8th. One analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, Pfizer presently has a consensus rating of “Moderate Buy” and a consensus price target of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.